Abstract:The current epidemic situation of coronavirus disease 2019 (COVID-19) still remains severe. As the National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of the Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang Province. Based on the present expert consensus carried out by the National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on "Four-Anti and Two-Balance" for clinical practice. The "Four-Anti and Two-Balance" strategy includes antivirus, anti-shock, antihypoxemia, and anti-secondary infection, and maintaining of water, electrolyte and acid/base balance and microecological balance. Simultaneously, an integrated multidisciplinary personalized treatment is recommended to improve therapeutic effects. The importance of early viral detection, dynamic monitoring of inflammatory indexes, and chest radiographs has been emphasized in clinical decision-making. Sputum was observed with the highest positive rate by reverse transcription-polymerase chain reaction (RTPRC). Viral nucleic acids could be detected in 10% of the patients' blood samples at the acute phase and 50% of patients had positive RT-PCR results in their feces. We also isolated live viral strains from feces, indicating potential infectiousness of feces. Dynamic cytokine detection was necessary to timely identify cytokine storms and for the application of the artificial liver blood purification system. The "Four-Anti and Two-Balance" strategy effectively increased cure rates and reduced mortality. Early antiviral treatment alleviated disease severity and prevented illness progression. We found that lopinavir/ritonavir combined with abidol showed antiviral effects against COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system was able to rapidly remove inflammatory mediators and block the cytokine storm. Moreover, it also contributed to the balance of fluids, electrolytes, and acids/bases and thus improved treatment efficacy during critical illness. For cases of severe illness, early and also short periods of moderate glucocorticoid administration was supported. Patients with an oxygenation index below 200mmHg were transferred to the intensive care unit. Conservative oxygen therapy was preferred and noninvasive ventilation (NIV) was not recommended. Patients with mechanical ventilation were strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was prescribed rationally and was not recommended, except for patients with a long course of disease, repeated fever, and elevated procalcitonin, similarly secondary fungal infections were of concern. Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased genus such as Lactobacillus and Bifidobacterium. Nutritional and gastrointestinal function should; therefore, be assessed for all patients. Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infections due to bacterial translocation. Anxiety and fear were common in patients with COVID-19. Therefore, we established a dynamic assessment and warning for psychological crises. We also integrated Chinese medicine in the treatment to promote rehabilitation. We optimized nursing processes for severe patients to promote their rehabilitation. Since viral clearance patterns after severe acute respiratory syndrome coronavirus 2 infections remained unclear, 2 weeks quarantine for discharged patients was required, and a regular following-up was also needed. These Zhejiang experiences and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work is warranted to further improve strategies of prevention, diagnosis, and treatment for COVID-19.

[Pharmaceutical care for severe and critically ill patients with COVID-19].

Clinical Characteristics and Treatment of Critically Ill Patients with COVID-19 in Hebei.

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience.

Clinical Interventions for Severe and Critical COVID-19: What Are the Options

Clinical Characteristics and Current Treatment of Critically Ill Patients with COVID-19 Outside Wuhan, China: A Multicenter, Retrospective, Observational Study

Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Chinese expert consensus on the diagnosis and treatment of severely and critically ill patients with coronavirus disease 2019

An Analytical Study of Drug Utilization, Disease Progression, and Adverse Events among 165 COVID-19 Patients.

On-ward participation of clinical pharmacists in a Chinese intensive care unit for patients with COVID-19: A retrospective, observational study

Application of Chinese Medicine in the Management of Critical Conditions: A Review on Sepsis

Critical care for severe coronavirus disease 2019: a population-based study from a province with low case-fatality rate in China

[Management of COVID-19: the Zhejiang experience]

Drug treatment of coronavirus disease 2019 (COVID-19) in China.

Current status and progress of 2019 novel coronavirus pneumonia Experience of treating severe cases of 2019 novel coronavirus pneumonia in Changde area

[Management of Corona Virus Disease-19 (COVID-19): the Zhejiang Experience].

Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019

COVID-19: Treating and Managing Severe Cases

Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, China

Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China

Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment